|
1.
|
Arnold U and Ulbrich-Hofmann R: Natural
and engineered ribonucleases as potential cancer therapies.
Biotechnol Lett. 28:1615–1622. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Leland PA and Raines RT: Cancer
chemotherapy - ribonucleases to the rescue. Chem Biol. 8:405–413.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Leland PA, Schultz LW, Kim BM, et al:
Ribonuclease A variants with potent cytotoxic activity. Proc Natl
Acad Sci USA. 95:10407–10112. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Turcotte RF and Raines RT: Interaction of
onconase with the human ribonuclease inhibitor protein. Biochem
Biophys Res Commun. 377:512–514. 2008. View Article : Google Scholar
|
|
5.
|
Singh UP, Ardelt W, Saxena SK, et al:
Enzymatic and structural characterisation of amphinase, a novel
cytotoxic ribonuclease from Rana pipiens oocytes. J Mol
Biol. 371:93–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ardelt W, Mikulski SM and Shogen K: Amino
acid sequence of an anti-tumor protein from Rana pipiens
oocytes and early embryos. Homology to pancreatic ribonucleases. J
Biol Chem. 266:245–251. 1991.PubMed/NCBI
|
|
7.
|
Dyer KD and Rosenberg HF: The RNase a
superfamily: generation of diversity and innate host defense. Mol
Divers. 10:585–597. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Ardelt W, Shogen K and Darzynkiewicz Z:
Onconase and amphinase, the antitumor ribonucleases from Rana
pipiens oocytes. Curr Pharm Biotechnol. 9:215–225. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Zhao H, Ardelt B, Ardelt W, Shogen K and
Darzynkiewicz Z: The cytotoxic ribonuclease onconase targets RNAi
(siRNA). Cell Cycle. 7:3258–3261. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Mikulski SM, Viera A, Ardelt W, et al:
Tamoxifen and trifluoroperazine (Stelazine) potentiate
cytostatic/cytotoxic effects of P-30 protein, a novel protein
possessing anti-tumor activity. Cell Tissue Kinet. 23:237–346.
1990.
|
|
11.
|
Rybak SM, Pearson JW, Fogler WE, et al:
Enhancement of vincristine cytotoxicity in drug-resistant cells by
simultaneous treatment with onconase, an antitumor ribonuclease. J
Natl Cancer Inst. 88:747–753. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Smolewski P, Bedner E, Du L, Hsieh TC, Wu
JM, Phelps DJ and Darzynkiewicz Z: Detection of caspases activation
by fluorochrome-labeled inhibitors: multiparameter analysis by
laser scanning cytometry. Cytometry. 44:73–82. 2001. View Article : Google Scholar
|
|
13.
|
Ardelt W, Ardelt B and Darzynkiewicz Z:
Ribonucleases as potential modalities in anticancer therapy. Eur J
Pharmacol. 625:181–189. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zwolińska M and Smolewski P: Onconase: a
ribonuclease with antitumor activity. Post Hig Med Dosw. 64:58–66.
2009.
|
|
15.
|
Michaelis M, Cinatl J, Anand P, et al:
Onconase induces caspase-independent cell death in chemoresistant
neuroblastoma cells. Cancer Lett. 250:107–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Pozarowski P, Huang X, Halicka DH, Lee B,
Johnson G and Darzynkiewicz Z: Interactions of fluorochrome-labeled
caspase inhibitors with apoptotic cells. A caution in data
interpretation. Cytometry A. 55:50–60. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ardelt B, Ardelt W, Pozarowski P, et al:
Cytostatic and cytotoxic properties of amphinase: a novel cytotoxic
ribonuclease from Rana pipiens oocytes. Cell Cycle.
6:3097–3102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Matoušek J: Ribonucleases and their
antitumor activity. Comp Biochem Physiol. 129C:175–191. 2001.
|
|
19.
|
Fredman P: Glycosphingolipid tumor
antigens. Adv Lipid Res. 25:213–234. 1993.PubMed/NCBI
|
|
20.
|
Johnson RJ, Chao T-Y, Lavis LD, et al:
Biochemistry. 46:10308–10316. 2007. View Article : Google Scholar
|
|
21.
|
Mikulski SM, Viera A, Darzynkiewicz Z, et
al: Synergism between a novel amphibian oocyte ribonuclease and
lovastatin in inducing cytostatic and cytotoxic effects in human
lung and pancreatic carcinoma cell lines. Br J Cancer. 66:304–310.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Deptala A, Halicka HD, Ardelt B, et al:
Potentiation of tumor necrosis factor induced apoptosis by
onconase. Int J Oncol. 13:11–16. 1998.PubMed/NCBI
|
|
23.
|
Ita M, Halicka HD, Tanaka T, Kurose A,
Ardelt B, Shogen K and Darzynkiewicz Z: Remarkable enhancement of
cytotoxicity of onconase and cepharanthine when used in combination
on various tumor cell lines. Cancer Biol Ther. 7:1104–1108. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ardelt B, Ardelt W and Darzynkiewicz Z:
Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle.
2:22–24. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ikemura K, Yamamoto M, Miyazaki S,
Mizutani H, Iwamoto T and Okuda M: MicroRNA-145
post-transcriptionally regulates the expression and function of
P-glycoprotein in intestinal epithelial cells. Mol Pharmacol.
83:399–405. 2013. View Article : Google Scholar
|
|
26.
|
Zhu X, Li Y, Shen H, Li H, Long L, Hui L
and Xu W: miR-137 restoration sensitizes multidrug-resistant
MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta
Biochim Biophys Sin (Shanghai). 45:80–86. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Bao L, Hazari S, Mehra S, Kaushal D, Moroz
K and Dash S: Increased expression of P-glycoprotein and
doxorubicin chemo-resistance of metastatic breast cancer is
regulated by miR-298. Am J Pathol. 180:2490–2503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Costanzi J, Sidransky D, Navon A, et al:
Ribonucleases as a novel pro-apoptotic anticancer strategy: Review
of the preclinical and clinical data for Ranpirnase. Cancer Invest.
23:643–650. 2005. View Article : Google Scholar : PubMed/NCBI
|
